StockData
Passage BIO, Inc. logo

Passage BIO, Inc. (PASG) stock

PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$4.22+0.09 (+2.18%)

Close on Nov 17, 2026Market cap $13.58MP/E –Yield –

Passage BIO operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Passage BIO's operating cash flow for the twelve months ending Jun 30, 2026 was -$33.50M. For fiscal 2025 it was -$31.51M. The highest annual figure on record is -$31.51M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$31.51M–
FY2024Dec 31, 2024-$47.96M–
FY2023Dec 31, 2023-$78.26M–
FY2022Dec 31, 2022-$118.21M–
FY2021Dec 31, 2021-$126.88M–
FY2020Dec 31, 2020-$80.52M–
FY2019Dec 31, 2019-$39.90M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.18M–
Q1 FY2026Mar 31, 2026-$12.99M–
Q4 FY2025Dec 31, 2025-$6.48M–
Q3 FY2025Sep 30, 2025-$4.85M–
Q2 FY2025Jun 30, 2025-$6.33M–
Q1 FY2025Mar 31, 2025-$13.85M–
Q4 FY2024Dec 31, 2024-$8.44M–
Q3 FY2024Sep 30, 2024-$7.45M–
Q2 FY2024Jun 30, 2024-$13.14M–
Q1 FY2024Mar 31, 2024-$18.93M–
Q4 FY2023Dec 31, 2023-$19.52M–
Q3 FY2023Sep 30, 2023-$19.16M–
Q2 FY2023Jun 30, 2023-$17.14M–
Q1 FY2023Mar 31, 2023-$22.45M–
Q4 FY2022Dec 31, 2022-$24.02M–
Q3 FY2022Sep 30, 2022-$23.40M–
Q2 FY2022Jun 30, 2022-$26.08M–
Q1 FY2022Mar 31, 2022-$44.71M–
Q4 FY2021Dec 31, 2021-$30.78M–
Q3 FY2021Sep 30, 2021-$41.06M–
Q2 FY2021Jun 30, 2021-$24.33M–
Q1 FY2021Mar 31, 2021-$30.72M–
Q4 FY2020Dec 31, 2020-$29.42M–
Q3 FY2020Sep 30, 2020-$17.53M–
Q2 FY2020Jun 30, 2020-$11.72M–
Q1 FY2020Mar 31, 2020-$21.85M–
Q4 FY2019Dec 31, 2019-$17.48M–
Q3 FY2019Sep 30, 2019-$11.42M–
Q2 FY2019Jun 30, 2019-$10.78M–
Q1 FY2019Mar 31, 2019-$214.00K–

More Passage BIO figures

See a number that looks wrong?